Drug Price Trends for NIACIN ER

Average Pharmacy Cost for NIACIN ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
NIACIN ER 1,000 MG TABLET	33342-0189-10	0.25101	EACH	2026-03-18
NIACIN ER 1,000 MG TABLET	00093-7394-98	0.25101	EACH	2026-03-18
NIACIN ER 1,000 MG TABLET	00093-7394-86	0.25101	EACH	2026-03-18

Market Analysis and Price Projections for NIACIN ER

Last updated: February 20, 2026

What is NIACIN ER?

NIACIN ER (extended-release niacin) is a lipid-lowering agent used primarily to treat dyslipidemia. It reduces low-density lipoprotein (LDL) cholesterol and triglycerides, while increasing high-density lipoprotein (HDL). Approved by the FDA in 2004, it is available as a lower-cost generic drug and under proprietary brands such as Niaspan.

Market Size and Demand Drivers

Current Market and Sales Data

• Estimated global sales in 2022: approximately $150 million.
• U.S. market share: roughly 85%, driven by established prescriber patterns.
• Prescription volume trends: stable over the past five years, with slight declines due to the rise of novel lipid-lowering agents.

Demand Drivers

• Prescriber preferences: strong adherence among cardiologists and primary care.
• Cardiovascular risk management: NIACIN ER is used alongside statins in high-risk patients.
• Regulatory environment: no recent restrictions or recalls, maintaining stable usage.

Competitive Landscape

• Generics: dominant, with competition leading to price compression.
• Brand Name (Niaspan): premium pricing, but declining market share.
• New entrants: development pipelines include combination therapies and alternative formulations.

Pricing Dynamics and Historical Trends

Current Price Points

• Average wholesale price (AWP) for a 30-day supply (500 mg, extended-release): approximately $35.
• Brand name Niaspan: up to $150 per month.

Price Trends (2018–2023)

Year	Average Price per 30-day Supply	Notable Changes
2018	$40	Slight increase due to generic market entry.
2020	$30	Price competition among generics reduced cost.
2022	$35	Stabilization despite generic abundance.
2023	$33	Slight decrease due to price negotiations.

Regulatory and Policy Environment

• No recent FDA restrictions.
• Some payers incentivize use of generics through formulary placement.
• Coverage policies favor lower-cost generics, exerting downward pressure on prices.

Market Projection and Price Outlook (2023–2028)

Market Trends

• Demand decline projected at approximately 2% annually due to increased use of PCSK9 inhibitors, PCSK9 monoclonal antibodies, and ezetimibe.
• Pricing stability expected for generics, with minor fluctuations within ±10%, barring new economic factors.

Price Projections

Year	Expected Price per 30-day Supply	Assumptions
2024	$33–$36	Marginal price fluctuation within 10%.
2025	$32–$35	Slight downward pressure persists.
2026	$31–$34	Continued generic competition.
2027	$30–$33	Further price stabilization.
2028	$29–$32	Market saturation, minimal price movement.

Key Influences on Pricing and Market Size

• Increased adoption of alternative lipid-lowering therapies.
• Patent expirations or formulation innovations may influence pricing.
• Healthcare policy shifts toward value-based care may impact formulary decisions.

Key Takeaways

• The current global NIACIN ER market is approximately $150 million, with stabilizing demand.
• Generic prices are around $33 per 30-day supply; brand pricing remains significantly higher.
• Market demand declines slowly, driven by shifts toward newer therapies.
• Prices are likely to remain stable or slightly decrease over the next five years, mainly influenced by generic competition and healthcare policies.
• Future growth prospects depend on market penetration of combination therapies and new lipid-lowering agents.

FAQs

Q1: What is the primary driver for prescribing NIACIN ER?
Cholesterol management in patients intolerant to statins or needing LDL and triglyceride reduction.

Q2: How does the price of NIACIN ER compare with alternative therapies?
Generic NIACIN ER costs about $33/month; alternatives like ezetimibe or PCSK9 inhibitors are significantly more expensive.

Q3: Will patent protection or exclusivity impact NIACIN ER prices soon?
Most formulations are off-patent; no pending patents are expected to significantly affect pricing.

Q4: How are insurance policies influencing NIACIN ER utilization?
Payers favor generics, leading to lower out-of-pocket costs for patients and encouraging prescriber preference for off-patent formulations.

Q5: Are new formulations or combinations likely to affect the NIACIN ER market?
Yes; combination drugs with statins or sustained-release formulations could shift demand towards newer options.

---

References

1. GlobalData. (2023). Pharmaceutical Market Analysis.
2. IQVIA. (2022). Medicines Data Report.
3. U.S. Food and Drug Administration. (2022). Drug Approval and Labeling.
4. MedTech Insight. (2023). Lipid-lowering therapies: Market trends.
5. Centers for Medicare & Medicaid Services. (2022). Drug Pricing and Reimbursement Policies.